{"entity":{"id":"nct07443397","kind":"trial","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","aka":[],"tldr":"A phase 3 trial of anlotinib in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","summary":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. is a phase 3, randomised interventional study registered as NCT07443397 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 134 participants, started 2025-08-29 and due to reach its primary completion in 2027-08-31. Interventions recorded: Anlotinib; Whole-brain Radiotherapy. Conditions listed: Whole-Brain Radiotherapy. Primary outcome: Intracranial progression-free survival. Lung eligibility wording from the registry: \"* Small cell lung cancer confirmed by pathology, with brain metastases diagnosed either at initial presentation or during treatment, and measurable disease according to RECIST criteria\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07443397","url":"https://clinicaltrials.gov/study/NCT07443397"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["antiangiogenic","imrt-igrt","kinase-inhibitors"],"targets":[],"drugs":["anlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07443397","phase":"3","setting":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in Small Cell Lung Cancer Patients: A Multicenter Phase III Trail.","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","enrolled":134,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07443397/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}